表皮生长因子受体基因多态性与表皮生长因子受体-酪氨酸激酶抑制剂抗癌药物不良反应相关性的研究  

The correlation between the polymorphisms in the epidermal growth factor receptor gene and the side effects of anticarcinogen of epidermal growth factor receptor tyrosine kinase inhibitor

作　　者：周艳秋 周云芝 张楠 管洁 秦芳 刘建坤 邹珩 王洪武 

机构地区：[1]煤炭总医院呼吸内科,100028 [2]煤炭总医院中心实验室,100028

出　　处：《心肺血管病杂志》2017年第5期364-368,共5页Journal of Cardiovascular and Pulmonary Diseases

基　　金：教育部"留学回国人员科研启动基金"[(2010)1561]

摘　　要：目的:探讨表皮生长因子受体(EGFR)基因多态性与表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-Tki)抗癌药物不良反应的相关性。方法:选择2013年1月至2015年5月,在我院使用EGFR-Tki(吉非替尼)治疗的121位非小细胞肺癌(NSCLC)患者.采用直接测序法检测EGFR基因内因子区CA-SSR基因多态性(SNPs),采用放大受阻突变系统(ARMS)检测EGFR基因外显子rs2293347 G/A,以及启动区-216 G/T,-191 C/A3个基因多态性。治疗过程中观察并分析患者的不良反应发生情况,评价基因多态性与不良反应之间的关系。结果:EGFR基因内含子区CA-SSR基因多态性与发生皮疹不良反应的严重程度具有显著的相关性(P=0.003),但与不良反应发生率无关。结论:EGFR基因内含子区CA-SSR基因多态性可以考虑应用于临床评估晚期非小细胞肺癌患者使用EGFR-Tki发生皮疹毒不良反应的严重程度。Objective：To investigate the correlation between the Polymorphisms in the epidermal growth factor receptor（EGFR） gene and the side effects of anticarcinogen of epidermal growth factor receptor tyrosine kinase inhibitor （EGFR-Tki）. Methods： The 121 patients with non small cell lung cancer （NSCLC） treated by EGFR-Tki- Gifitinib were selected from January 2013 to May 2015 in our hospital. The single nucleotide polymorphism of CA-SSR in the EGFR gene intron was detected by direct sequencing method. Genotyping of three single nucleotide polymorphisms （SNPs） , -216 G/T, -191 C/A in the EGFR gene promoter and rs2293347 G/A in the exon , was performed using the amplification refractory mutation system （ARMS）. Observed and analysed the adverse reactions in the patients in the course of treatment. Then explored the relationship between the polymorphisms in the EGFR gene and these adverse reactions. Results： There was significant difference be- tween the SNPs of CA-SSR in the EGFR gene intron and the severity of adverse reactions （P = 0. 003 ）. It was not related to the incidence of adverse reactions. Conclusion ： The polymorphism of CA-SSR in EGFR gene intron region can be used to evaluate the toxic and side effects of the Gifitnib in the patients with advanced nonsmall cell lung cancer.

关 键 词：表皮生长因子受体 吉非替尼 CA-SSR rs2293347 G/A 191C/A基因多态性 

分 类 号：R56[医药卫生—呼吸系统]